NCT06884306

Brief Summary

Prevalence of spontaneous bacterial peritonitis (SBP) varies from approximately 4% among asymptomatic patients to 30% among those hospitalized \[1, 2\].Previous studies explored the role of several biomarkers, such as tumor necrosis factor-α, procalcitonin, and fecal calprotectin, for prediction of SBP The NLR is speculated to reflect immune regulatory mechanism (lymphocytes) and ongoing inflammation (neutrophils) . Assessing the diagnostic value of NLR for liver disease has gained particular interest, namely, among patients with nonalcoholic fatty liver disease and hepatocellular carcinoma . Direct interaction between platelets and bacteria lead to platelet activation . Platelet activation leads to change of platelet shape with increase in platelet size and anisocytosis, and consequent increase in both mean platelet volume (MPV) and platelet distribution width (PDW) .Acute phase reactants, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), are elevated among patients with SBP, as a result of cytokine synthesis . Older patients, due to higher possibility of advanced liver disease and more frequent comorbidity, are more susceptible to SBP . The Department of Tropical Medicine (Mansoura University) developed a simple scoring system for prediction of SBP among cirrhotic patients with ascites, which include four variables: age, MPV, NLR, and C-reactive protein (CRP) . The independent predictors of SBP were age of at least 55 years, MPV of at least 8.5 fL, NLR of at least 2.5, and CRP of at least 40 mg/dL . The progression of hospitalized patients with SBP can lead to an in-hospital mortality rate of approximately 17% . Therefore, the sequelae of SBP highlight the increasing value of establishing reliable diagnostic biomarkers. The earlier the diagnosis, the lower the mortality rate.To our knowledge, only one, national study utilized MPV, NLR, and CRP for prediction of SBP among cirrhotic patients with ascites \[3\].We intend to further extend both the diagnostic utilities (by adding ESR to the previously mentioned tools) and the spectrum of prediction, to include mortality in addition to the development of SBP among cirrhotic patients with ascites. The study aims at developing a local scoring system (RSS) for the prediction of SBP and its related mortality among cirrhotic patients with ascites admitted to Al-Rajhy Liver Hospital (Assiut University). Our objective is to compare age, NLR, MPV, PDW, and CRP between cirrhotic patients with ascites complicated with SBP and those without SBP, and between surviving SBP patients compared to those with in-hospital mortality.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
1mo left

Started Apr 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Apr 2025Jul 2026

First Submitted

Initial submission to the registry

March 13, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 19, 2025

Completed
13 days until next milestone

Study Start

First participant enrolled

April 1, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Expected
Last Updated

March 19, 2025

Status Verified

March 1, 2025

Enrollment Period

1.1 years

First QC Date

March 13, 2025

Last Update Submit

March 13, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • local scoring system (RSS)

    developing a local scoring system (RSS) for the prediction of SBP mortality among cirrhotic patients with ascites admitted to Al-Rajhy Liver Hospital (Assiut University

    baseline

Study Arms (1)

study group

cirrhotic patients with Moderate-marked ascites, as determined by abdominal ultrasonography (US). SBP will be diagnosed based on detection of polymorph nuclear leukocytes (PMNs) \>250 cells/mcL and/or white blood cells (WBCs) \>500 cells/mcL by ascitic fluid examination.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

cirrhotic patients with Moderate-marked ascites, as determined by abdominal ultrasonography (US). SBP will be diagnosed based on detection of polymorph nuclear leukocytes (PMNs) \>250 cells/mcL and/or white blood cells (WBCs) \>500 cells/mcL by ascitic fluid examination.

You may qualify if:

  • include cirrhotic patients with Moderate-marked ascites, as determined by abdominal ultrasonography (US). SBP will be diagnosed based on detection of polymorph nuclear leukocytes (PMNs) \>250 cells/mcL and/or white blood cells (WBCs) \>500 cells/mcL by ascitic fluid examination.

You may not qualify if:

  • Pediatric patients (less than 18 years old) and patients older than 70 years Pregnant patients .
  • Etiology of ascites other than cirrhosis. 3-Receiving antibiotics and/or prophylaxis four weeks before admission. 4- Concurrent bacterial infection other than SBP. 5- Abdominal surgery 12 weeks before admission 6-Patients with neoplastic or hematological disease. 7- Patients who received bone marrow transplantation, chemotherapy, or radiotherapy four weeks before admission.
  • Conditions associated with increased MPV such as systemic hypertension, diabetes mellitus, dyslipidemia, peripheral vascular disease, thyroid disease, and therapy four weeks before admission with antiplatelet agents and nonsteroidal anti-inflammatory drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
residant doctor

Study Record Dates

First Submitted

March 13, 2025

First Posted

March 19, 2025

Study Start

April 1, 2025

Primary Completion

May 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

March 19, 2025

Record last verified: 2025-03